Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,858.00
Bid: 6,847.00
Ask: 6,850.00
Change: 1.00 (0.01%)
Spread: 3.00 (0.04%)
Open: 6,800.00
High: 6,921.00
Low: 6,779.00
Yest. Close: 6,857.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Wednesday newspaper round-up: FCA, AstraZeneca, Greece

The UK markets regulator has given his backing to asset managers fighting proposals that could see them labelled as potential threats to the financial system. Martin Wheatley, head of Britain's Financial Conduct Authority, said global regulators faced "big questions" that needed to be answered befor

3 Jun 15 07:29

CORRECTED-UPDATE 2-AstraZeneca would consider buying immune-therapy company - Bbg

(Corrects paragraph 6 to say "she" instead of "he") June 2 (Reuters) - AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body's immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday. An earli

2 Jun 15 18:20

UPDATE 2-AstraZeneca would consider buying immune-therapy company - Bbg

(Updates after Bloomberg corrects story) June 2 (Reuters) - AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body's immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday. An earlier version

2 Jun 15 18:12

CORRECTED-INSIGHT-Tests for new cancer drugs not reliable enough, doctors say

(Changes name of drug to Keytruda in second to last paragraph) By Deena Beasley CHICAGO, June 2 (Reuters) - Drugmakers including Bristol-Myers Squibb Co and Merck & Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but

2 Jun 15 17:12

UPDATE 1-AstraZeneca would consider buying company such as Juno-Bloomberg

(Adds details, share reaction) June 2 (Reuters) - AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc , Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. Juno's shares rose as much as 14.9 percent to $61. Seattle-based Juno,

2 Jun 15 15:21

BUZZ-Juno Therapeutics leads sector rally on M&A talk

** Juno Therapeutics up more than 13 pct on reported AstraZeneca interest in immuno-oncology sector ** Traders cite Astra CEO saying in interview to Bloomberg that saying companies like Juno could be of potential interest ** Bounce in Juno shares lifts peers Bellicum Pharma , up 5.2 p

2 Jun 15 14:59

AstraZeneca may consider buying company such as Juno - Bloomberg

June 2 (Reuters) - AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc , Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. The companies were not immediately available to comment. Juno is one among the few companies that are develo

2 Jun 15 14:57

RPT - INSIGHT-Tests for new cancer drugs not reliable enough, doctors say

(Repeats for additional subscribers) By Deena Beasley CHICAGO, June 2 (Reuters) - Drugmakers including Bristol-Myers Squibb Co and Merck & Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a bi

2 Jun 15 11:00

AstraZeneca Updates Industry Group On Immuno-Oncology Pipeline

2 Jun 15 07:02

INSIGHT-Tests for new cancer drugs not reliable enough, doctors say

By Deena Beasley CHICAGO, June 2 (Reuters) - Drugmakers including Bristol-Myers Squibb Co and Merck & Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers

2 Jun 15 05:00

CORRECTED-UPDATE 1-Large U.S. cancer trial to match genetic glitches to targeted drugs

(Corrects to remove reference to Novartis' ceritinib in paragraph 7, which is not in the trial) By Julie Steenhuysen CHICAGO, June 1 (Reuters) - The National Cancer Institute in July will start enrolling patients in a clinical trial seeking to match the underlying genetic defect driv

1 Jun 15 21:41

UPDATE 1-Large U.S. cancer trial to match genetic glitches to targeted drugs

(Adds information on second, related trial) By Julie Steenhuysen CHICAGO, June 1 (Reuters) - The National Cancer Institute in July will start enrolling patients in a clinical trial seeking to match the underlying genetic defect driving a person's tumor with one or more of 20 approved

1 Jun 15 16:52

FTSE 100 movers: Lloyds declines as state investment vehicle lowers stake, miners lower

UK shares were trading lower on Monday afternoon, ahead of a raft of US economic data, as weakness in mining, oil and insurance stocks outweighed gains made in the real estate, travel and electronics sectors. As of 15:30 BST, the FTSE 100 was trading 0.23% lower at 6,988. Lloyds registered losses a

1 Jun 15 13:49

Large U.S. cancer trial to match genetic glitches to targeted drugs

By Julie Steenhuysen CHICAGO, June 1 (Reuters) - The National Cancer Institute in July will start enrolling patients in a clinical trial seeking to match the underlying genetic defect driving a person's tumor with one or more of 20 approved or experimental drugs targeting that gene.

1 Jun 15 13:00

LONDON MIDDAY BRIEFING: Lloyds Buoyed By Latest Share Sale News

1 Jun 15 11:00

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.